Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen

Merck

3 Dow Jones Stocks to watch in the stock market in October 2022.

Best Stocks To Buy Right Now? 3 Dow Jones Stocks To Watch

Apple

Caterpillar

Chevron

Liberty Oilfield Services

McDonald's

Microsoft

Travelers

Select Energy Services

Two new Breakout Stocks for Week 41 with better than 10% short-term upside potential and one Dow 30 pick. Average cumulative returns now up to +106.5% YTD. This week one pick beat 10% in less than a week with ZYME at 10.84% peak gains despite high negative Momentum Gauge warnings.

MDA Breakout Stocks Week 41- October 2022: Short-Term Picks To Give You An Edge

Coca-Cola

NIKE

UnitedHealth Group

Visa

With markets down, the opportunity to invest in long-term blue-chip stocks is particularly strong. Will markets head further south in the coming weeks and months?

This Is the Best Time to Buy These 7 Long-Term Blue-Chip Stocks

Align Technology

If you have extra money to invest in the stock market right now, these two mainstays are worth considering.

Have $2,000? 2 Trusty Stocks to Buy Now

Accenture Plc

Cisco Systems

Mastercard

PepsiCo

Procter & Gamble

After two months off, I'm back with another edition of my monthly series, 10 Dividend Growth Stocks. I rank a selection of dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration.

10 Dividend Growth Stocks For October 2022

AbbVie

Their dividends should be much bigger in the future.

3 Great Dividend Stocks to Buy in October

General Mills

Kroger

Even though low-beta stocks have a lower return potential, they're great shields against volatility. After all, defense wins ballgames.

Sail Through Rough Waters With These 3 Low-Beta Stocks

Bank of America

iShares Core Dividend Growth ETF

Humana

JPMorgan Chase & Co

Morgan Stanley

iShares Short Maturity Bond ETF

Pfizer

iShares 1-3 Year Treasury Bond ETF

Funds investing in short-term Treasury bonds may be the best ETFs for investors in today's seesawing markets. The post Short-Term Treasury Rates Boost Appeal Of Bond ETFs appeared first on Investor's Business Daily.

Short-Term Treasury Rates Boost Appeal Of Bond ETFs

Amazon

Danaher

Disney

Devon Energy

General Electric

Macy's

Earlier this week, Matthew Tuttle's Tuttle Management filed to create two new exchange-traded funds (ETFs) to track the activity of CNBC's Mad Money host Jim Cramer. The first, called the Inverse Cramer ETF, will carry the symbol SJIM and bet against stocks recommended by Cramer.

Want to Bet Against Jim Cramer? Short These 10 Stocks.

Johnson & Johnson is a defensive healthcare juggernaut that fits the bill for numerous investor types. Rising cash flows will continue to fuel the growing dividend.

Johnson & Johnson: Stability In A Rather Unstable Market

Fastenal

Robert Half Int.

SAP SE

T. Rowe Price Group

Texas Instruments

With the massive paradigm shifts that erupted this year, more investors look toward cheap dividend stocks to buy. As inflationary forces diminished the dollar's purchasing power in the first half of this year, many sought to arrest this trajectory through passive income.

7 Dividend Stocks That Are Too Cheap to Ignore

Walgreens

York Water

Aged investors can sleep easy owning these rock-solid income stocks, which yield between 2% and 5.9%.

3 of the Safest Dividend Stocks Retirees Can Buy Right Now

iShares Core MSCI Emerging Markets ETF

SPDR S&P 500 ETF Trust

Bridgewater Associates' Ray Dalio made major headlines after he announced that he would cede control of the $150 billion hedge fund. The 73-year-old founder launched his hedge fund in 1975 from a two-bedroom apartment in New York and has more than cemented his place as one of the most successful fund managers of all time.

Ray Dalio Is Stepping Down. Here Are His Top 5 Stock Bets.

A U.S. bankruptcy judge has blocked New Mexico and Mississippi from pursuing lawsuits accusing Johnson & Johnson of misleading consumers about the safety of its talc products, such as its baby powder, for now.

U.S. judge temporarily blocks two state lawsuits over J&J talc marketing

These stocks should be big winners over the long term.

Dow Jones Bear Market: 3 Stocks to Buy Now

Alphabet

Eli Lilly

September has historically been the weakest month for the U.S. stock market, and 2022 was no different.

These Were The Five Best And Worst Performing Mega-Cap Stocks In September 2022

News for Johnson & Johnson Stock (JNJ)